In a randomized study, the combination of nivolumab and ipilimumab has demonstrated superior progression free survival compared to nivolumab alone in patients with melanoma. However, grade 3/4 AEs were 55% in patients treated with the combination versus 16.3% among patients treated with nivolumab al...